Q2 EPS Estimates for Cytokinetics Reduced by Leerink Partnrs
Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – Investment analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Cytokinetics in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will post earnings of ($1.34) per share for the quarter, down from their […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – Investment analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Cytokinetics in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will post earnings of ($1.34) per share for the quarter, down from their […]
